Halothane

Drug Class: Inhalation Anesthetic | Pharmacological Group: Halogenated Hydrocarbon

Mechanism of Action: Halothane produces general anesthesia by enhancing inhibitory neurotransmission and reducing excitatory neurotransmission in the central nervous system. It potentiates the action of GABA at GABA-A receptors, leading to increased chloride ion influx and hyperpolarization of neurons. It also inhibits excitatory glutamate receptors (NMDA and AMPA) and reduces neuronal firing. The exact molecular targets include multiple ion channels and receptors, resulting in a dose-dependent depression of the central nervous system, loss of consciousness, amnesia, analgesia, and muscle relaxation.

Pharmacodynamics: Halothane induces a dose-dependent depression of the central nervous system, leading to progressive loss of consciousness, analgesia, and muscle relaxation. It also causes dose-dependent cardiovascular depression, including decreased myocardial contractility, reduced cardiac output, and hypotension due to peripheral vasodilation. It sensitizes the myocardium to catecholamines, increasing the risk of arrhythmias. Respiratory depression occurs with increased depth of anesthesia, leading to decreased tidal volume and respiratory rate. Halothane also causes bronchodilation and depresses mucociliary function. It reduces cerebral metabolic rate and cerebral blood flow, and can increase intracranial pressure. It has a potent hepatic metabolic component, leading to potential hepatotoxicity.

Common:

• Hypotension
• Respiratory depression
• Cardiac arrhythmias (e.g., bradycardia, ventricular arrhythmias)
• Hypothermia
• Shivering during recovery
• Nausea and vomiting (in humans; less common in animals)

Serious / Severe:

• Malignant hyperthermia
• Halothane hepatitis (fulminant hepatic necrosis)
• Cardiac arrest
• Severe hypotension
• Cerebral edema (with increased intracranial pressure)

Rare:

• Seizures
• Anaphylaxis
• Renal dysfunction (due to fluoride ions)
• Immunosuppression

Signs of Toxicity:

• Severe hypotension
• Bradycardia or cardiac arrest
• Respiratory depression or apnea
• Hypothermia
• Cyanosis
• Coma
• Malignant hyperthermia (hyperthermia, muscle rigidity, tachycardia, acidosis)

Emergency Treatment Protocol: Immediately discontinue halothane administration and provide 100% oxygen. Support ventilation (assisted or controlled). Treat hypotension with intravenous fluids and vasopressors (e.g., dopamine, norepinephrine) as needed. Manage arrhythmias with appropriate antiarrhythmic agents (e.g., lidocaine for ventricular arrhythmias). For malignant hyperthermia, administer dantrolene (2-3 mg/kg IV) and initiate aggressive cooling. Monitor body temperature, blood gases, electrolytes, and cardiac function. Provide supportive care until recovery.

Withdrawal times are not well established for halothane; consult regulatory guidelines. In the US, halothane is not approved for use in food animals, but extra-label use may be permitted under AMDUCA with appropriate withdrawal times. A conservative withdrawal time of at least 7 days for meat and 3 days for milk is often recommended.

Storage Temperature: Store at controlled room temperature (15-30°C)

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Store in a tightly closed container, protected from light. Do not expose to excessive heat or open flames. Use only with a calibrated vaporizer.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for use in dogs, cats, and horses (as of historical data). Not approved for food animals.

Extra-Label (Off-Label) Use: Halothane is not approved for use in food animals in the US. Extra-label use in food animals is permitted under AMDUCA only by or on the order of a licensed veterinarian within a valid VCPR, with appropriate withdrawal times and residue avoidance. In non-food animals, it is a prescription drug.